Healthcare ❯ Pharmaceuticals

Biotechnology

Clinical Trials Drug Development Industry Analysis Biopharmaceuticals Vaccines Combination Treatments Genomics Cardiovascular Treatments Product Sales Drug Discovery Mental Health Rare Diseases Multiple Sclerosis Treatments

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

The Dutch buildout underscores a bet on scalable oral GLP-1 supply ahead of an orforglipron obesity filing targeted for late 2025.

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline